about
Drugs for treating urinary schistosomiasisUtility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic reviewProjecting the long-term impact of school- or community-based mass-treatment interventions for control of Schistosoma infectionNeuroparasitic Infections: Cestodes, Trematodes, and ProtozoansParasitic infections of the small intestine.Pulmonary paragonimiasis in Southeast Asians living in the central San Joaquin Valley.Schistosomiasis--an unusual cause of ureteral obstruction: a case history and perspective.Assessing the impact of misclassification error on an epidemiological association between two helminthic infectionsSchistosomiasis in the People's Republic of China: prospects and challenges for the 21st century.Modeling the effect of chronic schistosomiasis on childhood development and the potential for catch-up growth with different drug treatment strategies promoted for control of endemic schistosomiasisApplication and evaluation of a molecular approach for detection of the schistosomicidal effect of Mirazid® (myrrh) in the murine modelImported tropical diseases.Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro.Antibody responses to in vitro translation products following albendazole therapy for Echinococcus granulosus.Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.Anthelminthic agents: some recent developments and their clinical application.Abdominal wall hydatid cyst: case report and review of literature.Change in children's school behavior after mass administration of praziquantel for Schistosoma mansoni infection in endemic areas of western Kenya: A pilot study using the Behavioral Assessment System for Children (BASC-2).One hundred years of neglect in paediatric schistosomiasis.Disseminated abdominal hydatidosis: a rare presentation of common infectious disease.Cerebral and subcutaneous cysticercosis treated with albendazole.Neuroschistosomiasis myelopathy: case report.Evaluation of a method for induction of praziquantel resistance in Schistosoma mansoni.Endemic Hemoptysis.Efficient multicomponent reaction synthesis of the schistosomiasis drug praziquantel.Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa.[Epidemiology and clinical aspects of imported schistosomiasis]Impact of treatment with praziquantel, silymarin and/or beta-glucan on pathophysiological markers of liver damage and fibrosis in mice infected with Mesocestoides vogae (Cestoda) tetrathyridia.Systematic review of community-based, school-based, and combined delivery modes for reaching school-aged children in mass drug administration programs for schistosomiasis.Pharmacokinetics of new high-concentration and long-acting praziquantel oily suspensions after intramuscular administration in cattle.Promotion of rat hepatocarcinogenesis by praziquantel.Magnetically recyclable iron oxide nanoparticles for the α-cyanation of amines under acid-free conditions and the formal synthesis of praziquantel
P2860
Q24194447-2F16EC70-2986-4C74-8CBB-054B0365910BQ28477145-84ED19EF-025C-4BDC-84FA-59D1BB4C388BQ28485197-459579C0-7AA6-4F79-A0AE-54E283DA3142Q29039907-2F4718EA-262B-4E86-A97A-75044DCE317AQ30444909-48DE2964-5BD1-4EB0-B9FC-9D32051C7F69Q33560191-9DD0EDD0-BBAE-4A5C-99CE-95BF8DE89C89Q33723559-153E2181-8E3E-44BE-8BE1-A04ED231887BQ33863617-3EB8FDEC-BECB-451A-BF26-B41B7D52B054Q33941727-16CE96B0-100E-4B2C-A5FF-D38E110EC293Q34875689-6E9A573A-6B65-40A3-988B-1867F83EB592Q34961718-E40CF4B4-9C1E-4CBB-9D85-504EA96BAF59Q35011257-2EF71650-413D-474C-B16D-5C13E7E39EE1Q36442593-30A9D6D0-5FA4-442E-BEC9-6A47A201A694Q36754628-2D98C688-A1CA-4B2A-8667-4FD96A2C4AB6Q37094049-ABA81139-D379-4C38-86D8-00D8DA631642Q37767343-2214C9F7-0BD1-48DE-A745-01E66EEEBA09Q38041134-4841420C-90F6-45B2-8088-2D9EC5CB8825Q38660139-5D6AD2BC-F3BD-48BC-86F8-87ECFA69A89AQ38927082-09BDD8D9-8448-4E7A-AB17-04BCC5A041A8Q39202623-4EA9423E-CD4F-490E-A930-65E42917C89BQ40433513-6578D9D9-5C9F-4FE9-A197-0D88DF8F92AFQ40626219-975DD0F1-3164-42CC-95DB-D9247D327378Q41529687-366CC842-4A84-465A-A00D-F6D19BF4622BQ42527515-03D053BE-21CF-4A3B-BA53-639A99C153D6Q42906063-C15F40B2-D913-4F18-AF16-8AFB1D4D8E00Q46214180-4D44B037-28CC-4FAF-BB61-D7C7C5E01750Q46567614-D20FC9AE-44C8-427D-9E13-FFD4139DA3B3Q46660220-6FBA529E-6566-4E45-BA39-7705F3665798Q47122732-0043CC50-A881-48EA-9343-E40B0736D1B9Q51034558-2AB98D84-CE0E-483E-A57C-8C47764BF245Q55042091-E7F3C344-9408-4B65-BCE9-57A32C27EFEFQ58906622-6D6472CD-0E8A-4BB2-A4C0-267B7D871280
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Drugs five years later: praziquantel.
@en
type
label
Drugs five years later: praziquantel.
@en
prefLabel
Drugs five years later: praziquantel.
@en
P1476
Drugs five years later: praziquantel.
@en
P2093
Mahmoud AA
P304
P356
10.7326/0003-4819-110-4-290
P407
P577
1989-02-01T00:00:00Z